Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289254 | 0.87 | GAA (0.54) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4279819 | 0.80 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2TAAR1L3MBTL1 | |
| SCHEMBL14511667 | 0.80 | ALDH1A1 (0.48) | RAB9ANPC1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL13816928 | 0.78 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2TAAR1L3MBTL1 | |
| SCHEMBL953645 | 0.77 | MAPT (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5269033 | 0.77 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL13544467 | 0.76 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL5268958 | 0.76 | RAB9A (0.52) | RAB9ANPC1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5266006 | 0.75 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5269683 | 0.75 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | RAB9A 291/4885NPC1 1266/4885SMN1; SMN2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.